Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Journal of Virology
|
November 5, 2010
HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function
Mathieu F Chevalier, Boris Jülg, Augustine Pyo, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 15, 2011
Multilayered defense in HLA-B51-associated HIV viral control
YongHong Zhang, YanChun Peng, HuiPing Yan, et al.
Oncoimmunology
|
December 19, 2024
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
Jiajia Chen, Giuseppe Tarantino, Mariano Severgnini, et al.
AIDS Research and Human Retroviruses
|
June 27, 2017
HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights
Barbara L Shacklett, Cynthia A Derdeyn, Morenike Oluwatoyin Folayan, et al.
Immunity
|
October 21, 2016
Antiviral CD8<sup>+</sup> T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion
Srinika Ranasinghe, Pedro A Lamothe, Damien Z Soghoian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2021
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC
Bita Sahaf, Mina Pichavant, Brian H Lee, et al.
Blood
|
March 15, 2021
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
Livius Penter, Yi Zhang, Alexandra Savell, et al.
Blood
|
January 27, 2023
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
Livius Penter, Yang Liu, Jacquelyn O Wolff, et al.
The Lancet. Oncology
|
January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Arta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Journal of Virology
|
November 5, 2010
HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function
Mathieu F Chevalier, Boris Jülg, Augustine Pyo, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 15, 2011
Multilayered defense in HLA-B51-associated HIV viral control
YongHong Zhang, YanChun Peng, HuiPing Yan, et al.
Oncoimmunology
|
December 19, 2024
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
Jiajia Chen, Giuseppe Tarantino, Mariano Severgnini, et al.
AIDS Research and Human Retroviruses
|
June 27, 2017
HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights
Barbara L Shacklett, Cynthia A Derdeyn, Morenike Oluwatoyin Folayan, et al.
Immunity
|
October 21, 2016
Antiviral CD8<sup>+</sup> T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion
Srinika Ranasinghe, Pedro A Lamothe, Damien Z Soghoian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2021
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC
Bita Sahaf, Mina Pichavant, Brian H Lee, et al.
Blood
|
March 15, 2021
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
Livius Penter, Yi Zhang, Alexandra Savell, et al.
Blood
|
January 27, 2023
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
Livius Penter, Yang Liu, Jacquelyn O Wolff, et al.
The Lancet. Oncology
|
January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Arta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Page
of 3